subject: Anti-ischemic drug to be a breakthrough - drug research - the pharmaceutical industries [print this page] Anti-ischemic drug to be a breakthrough - drug research - the pharmaceutical industries
Recently, the Chinese Pharmaceutical Association, "Journal of Chinese Medicine," the new editorial board and other contractors Medicine Health reform and Pharmaceutical Development Summit Forum held in Hangzhou, Zhejiang Province. At the meeting, Vice Chairman of Chinese Pharmaceutical Association, the Chinese Academy of Medical Sciences, Institute Professor Wang Xiaoliang drugs report in the General Assembly stressed that the current anti-ischemic drug remains difficult, leading to many of the disappointing results of clinical trials to enhance such exploratory study of drugs, especially from Traditional Chinese medicine And Natural medicine It is feasible to find a breakthrough point move.
Pathophysiology of accelerated Xiao-Liang Wang introduced, neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, etc.), ischemic brain damage (stroke), psychiatric ( Depression , Schizophrenia, etc.), refractory epilepsy and other neuropsychiatric disorders is a serious major diseases affecting human health. As China's social and economic development and population aging problems, the incidence of these diseases increased year by year. Such as Parkinson's disease over 55 years of age the incidence rate of 1%, there are about 1.7 million patients; Alzheimer's disease over 60 years old the incidence rate of 1% to 2%, the total number of patients currently more than 500 million people; brain disease patients has reached 700 million, of which 2 / 3 left varying degrees of disability.
Ischemic cerebrovascular disease and brain damage causes are complex, many risk factors, mainly hypertension and cardiac dysfunction associated with heart failure, followed by dyslipidemia, diabetes, obesity and other such genetic , smoking, alcohol consumption, low temperature and high pressure factor. In view of ischemic cerebrovascular disease and the high incidence of significant harm, since the 80s of last century, there has been accelerated on the pathophysiology of cerebral ischemia disease, the pace of research. Meanwhile, related research and development of therapeutic drugs have rapid progress. For example, scientists propose to release a large number of neuronal excitability Amino acids (Excitatory amino acid theory), ischemic inflammatory reaction (inflammation theory), free radical induced damage (free radical theory), ischemia induced apoptosis (apoptosis theory), energy metabolism and calcium overload involved ischemic injury (calcium overload theory), and other theories, these theories pave the way for the research a good foundation.
Development process bottlenecks
Current acute ischemic cerebrovascular diseases are the main strategies and approaches to promote revascularization, anti-platelet aggregation, neuroprotective, neurotrophic, and scavenging free radicals and so on. Improve the cerebral circulation of drugs, including: anti-platelet aggregation drugs, such as cyclooxygenase inhibitors (aspirin), phosphodiesterase inhibitor (dipyridamole), membrane protein b / a (GP b / a) receptor antagonist (abciximab) ,5-HT2 receptor antagonist (by Mo Pami, fluoxetine, maprotiline); anticoagulant drugs, such as oral anticoagulants (warfarin, dicoumarol , double benzene double ketone, etc.), non-oral anticoagulants (low molecular weight heparin); thrombolytic drugs, such as the first generation of thrombolytic agents (urokinase, streptokinase), second-generation thrombolytic agents (recombinant tissue plasminogen activator), third-generation thrombolytic drugs (reteplase); fibrinolytic drugs, such as defibrase Batroxobin lumbrokinase etc.; vasodilators, such as methyl yellow Purine Derivative, receptor antagonist. Protection of brain tissue drugs, including: brain protective agents, such as oxygen free radical scavengers (superoxide dismutase, dexamethasone, mannitol, vitamin E and Vitamin C , Edaravone chant), excitatory amino acid receptor antagonist (N-methyl-D-aspartate (NMDA) receptor antagonists and two categories of non-NMDA receptor antagonist), calcium antagonists
